Entera Bio Ltd (ENTX) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Entera Bio Ltd's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Entera Bio Ltd's ROI in the second quarter of 2026? Entera Bio Ltd achieved a return on average invested assets (ROI) of 15.99 % in its second quarter of 2026, which is below Entera Bio Ltd's average return on investment, which stands at 39.26%.
ROI decreased relative to the period ending Mar 31 2026, due to the decline in net income.
Within the Healthcare sector 69 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 21 to 53.
Introducing Dr. Rachel B Wagman: A Leading Clinical Advisor Joins Entera Bio s Scientific Advisory Board JERUSALEM, May 15, 2024 - Entera Bio Ltd. (NASDAQ: ENTX), a pioneering company in the development of orally delivered peptides and small therapeutic proteins, has recently announced the appointment of Dr. Rachel B Wagman, MD, FACE, FACP, as their Key Clinical Advisor and a distinguished member of its Scientific Advisory Board. With over two decades of experience in metabolic bone disease and women s health research and drug development, Dr. Wagman s addition to Entera Bio s team promises to drive significant advancements in their mission to revolutionize oral drug delivery. Dr. Wagman s remarkable track record in the field of metabolic bone disease speaks for itself. Throughout her career, she has successfully propelled the development of five molecules, including teriparatide (Forteo), denosumab (Prolia), and romosozumab (Evenity), through the entire clinical development process, from initial stages to registration and lifecycle management. Her expertise and leadership have been instrumental in bringing cutting-edge treatments to market, providing hope and life-changing options to patients suffering from osteoporosis.
Entera Bio Ltd., a frontrunner in the development of orally delivered peptides and therapeutic proteins, recently disclosed that it has been granted a 180-day extension by the Nasdaq Stock Market LLC to regain compliance with the minimum bid price requirement. This extension showcases the company s commitment to meeting the necessary criteria for continued listing on the Nasdaq Capital Market. Additionally, the article highlights Entera Bio s remarkable return on investment (ROI) in the third quarter of 2023, surpassing its average ROI. This article will delve into the facts surrounding these developments and assess their impact on the company.
1. Nasdaq Extension: Entera Bio has received an extension from the Nasdaq Stock Market LLC to regain compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rule 5550(a)(2). The extension provides the company with 180 calendar days to meet this requirement, enabling it to maintain its listing on the Nasdaq Capital Market. This signifies Nasdaq s recognition of the company s adherence to other listing prerequisites and their confidence in Entera Bio s potential.
Entera Bio Secures $6.6 Million in Private Placement, Extending Cash Runway through 2025 Jerusalem-based biopharmaceutical company, Entera Bio Ltd. (NASDAQ: ENTX), has successfully concluded a private placement offering on December 22, 2023, raising approximately $6.6 million in gross proceeds. The placement involved existing and new investors who purchased 7,916,879 units at a price of $0.835 per unit. This recent financing will significantly extend Entera s cash runway, ensuring the company s financial stability through 2025. Entera Bio is recognized as a pioneer in the development of orally delivered peptides and therapeutic proteins. The company s innovative oral drug delivery technology has the potential to revolutionize the pharmaceutical industry by offering non-invasive and patient-friendly alternatives to injectable medications.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
